These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3658520)

  • 1. The meaning of FDA approval.
    Fischer RG
    Pediatr Nurs; 1987; 13(5):360. PubMed ID: 3658520
    [No Abstract]   [Full Text] [Related]  

  • 2. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA, off-label use, and informed consent: debunking myths and misconceptions.
    Beck JM; Azari ED
    Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA in hot water again over cost of proposed drug labeling rule.
    Demkovich LE
    Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426
    [No Abstract]   [Full Text] [Related]  

  • 7. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.
    Binder GM
    Curr Opin Biotechnol; 1999 Jun; 10(3):303-6. PubMed ID: 10361077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA acts on estrogen, progestin labeling.
    FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006
    [No Abstract]   [Full Text] [Related]  

  • 11. Implications for the FDA/Center for Veterinary Medicine (CVM).
    Geyer RE
    J Am Vet Med Assoc; 1993 May; 202(10):1718-23. PubMed ID: 8514592
    [No Abstract]   [Full Text] [Related]  

  • 12. Current FDA policy on use of human-labeled drugs in animals.
    Teske RH
    J Am Vet Med Assoc; 1993 May; 202(10):1632-3;discussion 1634. PubMed ID: 8514570
    [No Abstract]   [Full Text] [Related]  

  • 13. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
    Spencer HM
    Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546
    [No Abstract]   [Full Text] [Related]  

  • 14. Professional drug labeling.
    Terry M
    J Am Vet Med Assoc; 1993 May; 202(10):1711-2;discussion 1713-7. PubMed ID: 8514591
    [No Abstract]   [Full Text] [Related]  

  • 15. Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.
    Fed Regist; 1999 Aug; 64(158):44653-8. PubMed ID: 10558603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 17. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA commissioner discusses issues of concern to hospital pharmacists. Interview by William A. Zellmer.
    Goyan JE
    Am J Hosp Pharm; 1980 May; 37(5):738-40 contd. PubMed ID: 7386484
    [No Abstract]   [Full Text] [Related]  

  • 19. How does the FDA affect you and your practice?
    Novitch M
    Leg Aspects Med Pract; 1979 Mar; 7(3):23-6. PubMed ID: 423685
    [No Abstract]   [Full Text] [Related]  

  • 20. Compounding forum: FDA-CVM hears veterinarians' views.
    J Am Vet Med Assoc; 1993 Nov; 203(10):1367-72. PubMed ID: 8276690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.